Inova introduces minimally invasive tricuspid valve replacement to the region

By InovaNewsroom | March 31, 2026 |

Inova’s Structural Heart and Valve Disease Program is among the region’s first to offer transcatheter tricuspid valve replacement (TTVR). This exciting milestone expands the range of minimally invasive cardiac procedures available at Inova to now include not only tricuspid valve repair but also replacement of the valve. “This is the first replacement technology alternative to…

Read More

Inova plays a key role in trial of innovative treatment for tricuspid valve regurgitation that is now approved by the FDA

By InovaNewsroom | April 17, 2024 |

Update as of April 24, 2024: Inova’s structural heart team has now completed the first case in the Washington, DC region since the FDA approved a new device to treat tricuspid regurgitation (TR). Inova Schar Heart and Vascular’s Structural Heart/Valve Disease Program was among the top enrollers in the TRILUMINATE™ Pivotal Trial demonstrating the safety…

Read More

Inova’s Minimally Invasive Surgical Options Help Patients with Heart Valve Disease

By Eric Sarin, MD | February 14, 2022 |

Eric L. Sarin, MD, is a cardiac and thoracic surgeon with Inova Heart and Vascular Institute (IHVI). He is Section Chief of Adult Cardiac Surgery, Co-Director of the Structural Heart and Valve Program and Co-Director of Cardiovascular Research.  Matthew W. Sherwood, MD, MHS, is an Inova interventional cardiologist, Director of Inova’s Left Atrial Appendage Closure/WATCHMAN…

Read More